Skip to content

Capsaicin Cough Threshold in Chronic Cough Due to Postnasal Drip

Capsaicin Cough Sensitivity, Airway Inflammation and Neurogenic Peptides in Chronic Cough Associated With Postnasal Drip

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00588627
Enrollment
25
Registered
2008-01-08
Start date
2006-03-31
Completion date
2008-12-31
Last updated
2010-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Nasal Drip

Keywords

Chronic cough, Post nasal drip

Brief summary

This study is being done to find out why some people with mucus dripping down the back of their throat have a nagging cough while others do not cough.

Detailed description

The objective of the protocol is to determine the pathogenesis of cough in diseases of the aerodigestive tract. There were over 24 million ambulatory chronic cough visits nationally in 1991 and over 8,000 visits in 2004 at MCR. Current guidelines for chronic cough are based on case series and on empirical expert opinions. Studies have implicated mucosal inflammation, heightened sensitivity of capsaicin cough receptors on peripheral nerves and elaboration of inflammatory mediators including tussigenic neuropeptides. There are gaps in our knowledge of what triggers cough in many disease states. For example, postnasal drip syndrome has been estimated to account for 70% of chronic cough, yet it is known that not all patients with postnasal drip have chronic cough. Our hypothesis is that there must be critical factor/s that cause cough in one patient with postnasal drip but not in another. This study will evaluate whether there exists differences in capsaicin cough sensitivity, neuropeptides levels and mucosal inflammation in patients with postnasal drip and chronic cough and compared to its natural control group, subjects with postnasal drip with and without chronic cough. After standard therapy to eliminate postnasal drip, repeat measurement of capsaicin sensitivity and nitric oxide levels will be obtained. There is a critical need to determine the mechanisms underlying cough for better management. The study results will provide insight and fill gaps in our knowledge and will serve to advance future work evaluating mechanisms of cough in other disease states including asthma, GERD, interstitial lung disease and smokers.

Interventions

None listed

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Postnasal Drip with chronic cough: 1. Postnasal drip by rhinoscopy 2. Cough by visual analog scale. 3. Patients have to be 18 years old or older. 4. Cough-variant asthma must be excluded by a negative methacholine challenge test within one year, or documented failure of chronic cough to resolve after administration of inhaled corticosteroid (\> one-month duration). Asthma is defined by the ATS guidelines. 5. Subjects must have a negative chest radiogram or Chest CT scan within 6 months. 6. No active GERD symptoms (\< 7 RSI score) & a stable dose of Proton Pump Inhibitor (4 weeks). Eligibility Criteria of Postnasal Drip without cough: 7. Postnasal drip by rhinoscopy 8. No cough by visual analog scale. 9. Patients have to be 18 years old or older.

Exclusion criteria

* Subject

Design outcomes

Primary

MeasureTime frame
We hypothesize that capsaicin cough sensitivity is increased in patients with PND-CC compared to subjects with PND without cough and that cough sensitivity to capsaicin will decrease with treatment for postnasal drip.Endpoint

Secondary

MeasureTime frame
We hypothesize that neurogenic inflammation is increased in patients with PND-CC compared to subjects with PND alone.Endpoint
We hypothesize that nasal mucosal inflammation is increased in patients with PND-CC compared to subjects with PND alone, and that nasal mucosal inflammation will be decreased following treatment for postnasal treatment.Endpoint

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026